HER2-Positive Early Stage Breast Cancer Recruiting Phase 3 Trials for Trastuzumab deruxtecan (DB14962)

Also known as: HER2-Positive Early Breast Cancer / HER2-positive early-stage breast cancer / Early Stage HER2+ Breast Cancer / HER2 Positive Early Breast Cancer

IndicationStatusPhase
DBCOND0063722 (HER2-Positive Early Stage Breast Cancer)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs